SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings.
Jefferies London Healthcare Conference (November 14 – 16, 2023)
Location: Waldorf Hilton, London, UK
Format: Fireside Chat
Date and Time: Wednesday, November 15, 2:30-2:55 PM GMT
Webcast: https://wsw.com/webcast/jeff287/eras
6th Annual Evercore ISI HealthCONx Conference (November 28 – 30, 2023)
Location: Kimpton Epic Hotel, Miami, FL
Format: Fireside Chat
Date and Time: Tuesday, November 28, 11:15-11:35 AM ET
Webcast: https://wsw.com/webcast/evercore39/eras
An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.63 |
Daily Change: | 0.04 1.54 |
Daily Volume: | 2,924,133 |
Market Cap: | US$455.940M |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB